Analyst Cerena Chen from Wells Fargo maintained a Buy rating on Axsome Therapeutics (AXSM – Research Report) and keeping the price target at $165.00.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Cerena Chen’s rating is based on the understanding that the refusal to file for AXS-14 in fibromyalgia was due to trial design issues rather than data quality, indicating a potential opportunity for Axsome Therapeutics despite the setback. The FDA’s concern was with the flexible-dose and short duration of one trial, but not with the positive results, suggesting that with a revised trial design, the path to approval remains viable.
Moreover, the situation with AXS-14 does not affect the submission process for AXS-05, which is under a different division focused on psychiatry. The feedback for AXS-05 has been positive, with the supplemental NDA filing on track, reinforcing confidence in Axsome’s strategic direction and contributing to the Buy rating.
According to TipRanks, Chen is ranked #5747 out of 9593 analysts.
In another report released yesterday, Oppenheimer also maintained a Buy rating on the stock with a $183.00 price target.
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue